Also found in: Medical.
MCP-1Monocyte Chemoattractant Protein-1
MCP-1Monocyte Chemotactic Protein-1
MCP-1Macrophage/Monocyte Chemoattractant Protein-1 (immunology)
References in periodicals archive ?
The aim of this study was to investigate possible correlations between polymorphisms in the genes encoding for MCP-1, RANTES, SDF-1, and CCR5 and breast cancer clinical phenotypes, specifically the ability of genetic analysis to identify a subgroup of breast cancer patients with a disease that appears more aggressive or prone to metastasize.
Previous studies demonstrated some association between cytokines IL-1[beta], TNF-[alpha] and MCP-1 and schizophrenia, however, few studies have focused on predicting response to antipsychotics by testing peripheral blood cytokines.
sup][4],[5] Since MCP-1 promotes atherosclerosis, inhibition of MCP-1 may be effective in lowering atherosclerotic risk associated with obesity.
Interestingly, levels of MCP-1 and CCR2 returned to baseline or lower by 16 weeks in mice exhibiting movement-provoked pain behaviors.
MCP-1 can be induced in numerous cell types, including vascular endothelial cells, smooth muscle cells, monocytes/macrophages and cardiacmyocytes (Xia and Frangogiannis 2007).
Levels of TNF-a MCP-1, RBP-4 were also lower in the ChromeMate group compared to the control group; the chromium picofinate group did not experience any reduction in those markers.
No statistically significant differences were found between groups at baseline in clinical measurements, GCF levels of MCP-1 and RANTES and demographics, with the exception of race (p=0.
Additionally, CRP has been postulated to have a causal role in atherosclerosis (12-14) through the induction of MCP-1 (15) and tissue factor (TF) expression (16).
Previously completed studies in animal models of diabetes and lupus nephritis demonstrate that treatment with Spiegelmer([R]) MCP-1 antagonists significantly delay decline in kidney function as well as disease progression.
to directly demonstrate that MCP-1 critically contributes to failure of an AV fistula," the researchers write.
Because IL-8, MCP-1, EGF, and VEGF may be used as diagnostic biochemical markers, the main factors influencing the biological variation of these markers and adequate reference values must be established.
NASDAQ: CGEN) announced today that it will present experimental results for its previously disclosed CGEN-54, an MCP-1 antagonist therapeutic candidate, at GTCBio's 5th Cytokines and Inflammation Conference (January 29-30, 2007, Breckenridge, Colorado).